The Nigeria Renal Risk Reduction (R3) Trial: An Update

Muktar Aliyu, M.D., M.P.H., Dr.P.H.

Associate Director for Research,
Vanderbilt Institute for Global Health
Associate Professor, Health Policy and Medicine
Vanderbilt University Medical Center

This study seeks to determine the optimal means to manage and thereby reduce the risk of kidney and potentially other end organ complications among genetically at-risk northern Nigerian HIV-infected adults. Based on data from the diabetic literature using medications that block the renin angiotensin aldosterone system (RAAS), this trial is evaluating whether or not RAAS inhibition (with lisinopril) in HIV-infected adults produces similarly promising results.